Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks
2016
Abstract
Of the 224 patients who were randomized, 171 (86 teriparatide, 85 risedronate) were included in the analysis. The teriparatide group completed the TUG test in a shorter time at 6, 12, 18, and 26 weeks.
They also reported less pain on a visual analog scale immediately after the TUG test at 12 and 18 weeks. Radiographic healing at 6, 12, and 26 weeks, mechanical failure of the implant (teriparatide, 7; risedronate, 8), loss of reduction (teriparatide, 2; risedronate, 4), and nonunion (0 cases) were not significantly different.